Rogerio, you were one of the people responsible for integrating two well-established companies in the Brazilian market with the acquisition of Exel by DHL in late…
In Conversation
You are General Manager for Thailand and Vietnam; two markets that certainly interest companies but at a very different stage of development. What are according to…
Big news last year; Takeda bought Nycomed in what has been seen as a game changing acquisition for the pharma world. How have you seen this…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a…
To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz…
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well…
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of…
What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche…
